LLY · 10-Q · 2026Q2 · Full report

Product Revenue - Mounjaro

ELI LILLY & Co · 2026-08-05 · Importance 69 · Surprise 64 · In source text

Mounjaro generated $9,943 million in second-quarter 2026 revenue, compared with $5,199 million in the second quarter of 2025, and $18,605 million for the first six months, compared with $9,041 million. U.S. Mounjaro revenue increased 45% in the quarter and 51% year to date, reflecting strong demand despite lower realized prices. Outside-U.S. revenue increased to $5.2 billion in the quarter and $9.6 billion year to date from $1.9 billion and $3.1 billion, respectively. The addition of Mounjaro to China's National Reimbursement Drug List increased volume but pressured realized prices.

Key facts

• Mounjaro revenue for the six months ended June 30, 2026: Total $18,605 million; U.S. $9,024 million; Outside U.S. $9,582 million; compared with total $9,041 million in the prior year period. source
• Mounjaro revenue for the three months ended June 30, 2026: Total $9,943 million; U.S. $4,791 million; Outside U.S. $5,152 million; compared with total $5,199 million in the prior year period. source
• Revenue of Mounjaro increased 51 percent in the U.S. during the six months ended June 30, 2026. source
• Revenue of Mounjaro increased 45 percent in the U.S. during the three months ended June 30, 2026. source

Impact estimates